China’s Anti-Monopoly Efforts To Focus On Six Sectors Including Pharma
This article was originally published in PharmAsia News
Executive Summary
China’s National Development and Reform Commission’s anti-price monopoly efforts will focus on six industries including pharma, according to an NDRC price regulation and anti-monopoly official.